echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Roche's innovative anti-influenza drug Sufuda® was officially approved in China

    Roche's innovative anti-influenza drug Sufuda® was officially approved in China

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 29, Roche China announced that its innovative flu drug Sufuda® (English trade name: Xofluza®, Chinese generic name: Mabaloxavir) has been formally approved by the China National Medical Products Administration for the treatment of 12 years of age and The above acute uncomplicated influenza patients include those who are at high risk of influenza complications.


    Influenza is a common acute respiratory infectious disease with serious consequences.


    Mabaloxavir is an innovative cap-shaped structure-dependent endonuclease inhibitor.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.